Gynecomastia during imatinib mesylate treatment for gastrointestinal stromal tumor: a rare adverse event
<p>Abstract</p> <p>Background</p> <p>Imatinib mesylate has been the standard therapeutic treatment for chronic myeloid leukemia, advanced and metastatic gastrointestinal stromal tumor (GIST). It is well tolerated with mild adverse effects. Gynecomastia development durin...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2011-11-01
|
| Series: | BMC Gastroenterology |
| Online Access: | http://www.biomedcentral.com/1471-230X/11/116 |